Literature DB >> 1827961

Effect of antitumor surgery on soluble interleukin-2 receptor serum levels.

F Brivio1, P Lissoni, D Mancini, E Tisi, G Tancini, S Barni, V Nociti.   

Abstract

Surgically induced immunosuppression may play a role in cancer, because of the possible existence of micrometastases at the time of surgical removal of tumors. Antitumor immune reactions are mediated by interleukin-2 (IL-2). IL-2 acts on a specific IL-2 cell surface receptor; moreover, a soluble form of IL-2 receptor (sIL-2R) can be released in the blood. This study was carried out to evaluate the effect of surgery on sIL-2R serum levels in patients with operable solid tumors. A total of 48 patients with cancer and 11 controls who underwent major surgery for non-neoplastic disease were evaluated before and 7 days after surgery. Serum mean levels of sIL-2R were significantly higher after than before surgery in both the cancer and control groups. No correlation was seen between surgery-induced changes in sIL-2R and in T lymphocyte subsets. Because of its capacity of binding to IL-2, the increased blood concentrations of sIL-2R could reduce the IL-2 availability and negatively affect antitumor immune reactions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827961     DOI: 10.1016/0002-9610(91)91113-w

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  6 in total

1.  Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.

Authors:  N Müller; M Empl; M Riedel; M Schwarz; M Ackenheil
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 2.  New Insights on Tramadol and Immunomodulation.

Authors:  Iqira Saeed; Adam La Caze; Markus W Hollmann; Paul N Shaw; Marie-Odile Parat
Journal:  Curr Oncol Rep       Date:  2021-08-27       Impact factor: 5.075

3.  Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients.

Authors:  Luca Degrate; Cinzia Nobili; Claudio Franciosi; Roberto Caprotti; Fernando Brivio; Fabrizio Romano; Biagio Eugenio Leone; Rosangela Trezzi; Franco Uggeri
Journal:  Langenbecks Arch Surg       Date:  2008-08-01       Impact factor: 3.445

4.  Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer.

Authors:  M Shibata; M Takekawa; S Amano
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

5.  Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.

Authors:  S Mariotti; G Barbesino; P Caturegli; M Marinò; L Manetti; L Fugazzola; F Pacini; A Pinchera
Journal:  J Endocrinol Invest       Date:  1994-12       Impact factor: 4.256

6.  Immunologic response to tumor ablation with irreversible electroporation.

Authors:  Xiaoxiang Li; Kui Xu; Wei Li; Xiuchun Qiu; Baoan Ma; Qingyu Fan; Zhao Li
Journal:  PLoS One       Date:  2012-11-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.